Skip to main content
. Author manuscript; available in PMC: 2009 Jun 15.
Published in final edited form as: Adv Enzyme Regul. 2007 Mar 26;47:64–103. doi: 10.1016/j.advenzreg.2006.12.013

Table 4.

Differences in IC50 in doxorubicin sensitive and resistant FL/ΔAkt:ER*(Myr+)+ΔRaf-1:AR cells1

Cell Line→ Doxo-Sensitive Doxo-Resistant Fold Difference
Drug↓
Doxorubicin 25 nM 75 nM 3X
Daunorubicin 12 nM 30 nM 2.5X
Paclitaxel 3 nM 18 nM 6X
1

Determined by plating 2500 cells/well in 96 well plates in phenol red free RPMI+10% FBS + 500 nM 4HT +100 nM Test and serial 2-fold dilutions (n=12 dilutions) at 8 wells per each drug concentration. MTT analysis was performed after 4 days of incubation and results were normalized to untreated cells. These experiments differ from those presented in Tables 1, 2 & 3 as in those cases the cells were plated in IL-3.